ST诺泰(688076.SH)：依帕司他片获得药品注册证书

Core Viewpoint - ST诺泰 has received approval from the National Medical Products Administration for the drug registration certificate of Ipatasertib, which is indicated for diabetic neuropathy [1] Group 1: Product Information - Ipatasertib is a reversible non-competitive inhibitor of aldose reductase, selectively inhibiting the enzyme [1] - The drug works by inhibiting the accumulation of sorbitol in red blood cells of patients with diabetic peripheral neuropathy, thereby improving patients' subjective symptoms and neurological dysfunction [1]